The U.S. Food and Drug Administration revealed the first nine recipients of its Commissioner’s National Priority Voucher (CNPV) pilot program, a fast‑track mechanism intended to deliver regulatory decisions within weeks for products addressing national priorities. The list includes Disc Medicine’s NDA for bitopertin and other high‑profile submissions, potentially accelerating approvals into late 2025. MedCity and BioCentury reported on the program and FDA statements: qualifying products must meet criteria such as addressing an unmet public‑health need or boosting domestic manufacturing. Stocks of companies on the list reacted intraday to the announcement, reflecting the market view of accelerated timelines’ commercial value. Industry stakeholders will watch how the FDA manages resource allocation and maintains review rigor while testing this compressed timeline, and whether the pilot sets a precedent for future prioritization schemes.